The prognostic significance of hypertension at diagnosis in children with wilms tumor

References

1. ↵
   1. Horner MJ,
   2. Ries LA,
   3. Krapcho M,
   4. Neyman N,
   5. Aminou R,
   6. Howlader N,
   7. et al.

   (2009) SEER Cancer Statistics Review 1975-2006 (National Cancer Institute, Bethesda (MD)) Available from URL: http://seer.cancer.gov/archive/csr/1975_2006/.
2. ↵
   1. Scott RH,
   2. Stiller CA,
   3. Walker L,
   4. Rahman N

   (2006) Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 43:705–715.

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. Smith MA,
   2. Seibel NL,
   3. Altekruse SF,
   4. Ries LA,
   5. Melbert DL,
   6. O’Leary M,
   7. et al.

   (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28:2625–2634.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Metzger ML,
   2. Dome JS

   (2005) Current therapy for Wilms’ tumor. Oncologist 10:815–826.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Breslow N,
   2. Sharples K,
   3. Beckwith JB,
   4. Takashima J,
   5. Kelalis PP,
   6. Green DM,
   7. et al.

   (1991) Prognostic factors in nonmetastatic, favorable histology Wilms’ tumor: Results of the Third National Wilms’ Tumor Study. Cancer 68:2345–2353.

   OpenUrlCrossRefPubMed
6. ↵
   1. Dome JS,
   2. Perlman EJ,
   3. Graf N

   (2014) Risk stratification for wilms tumor: current approach and future directions. Am Soc Clin Oncol Educ Book, 215–23.
7. ↵
   1. Madre C,
   2. Orbach D,
   3. Baudouin V,
   4. Brisse H,
   5. Bessa F,
   6. Schleiermacher G,
   7. et al.

   (2006) Hypertension in childhood cancer: a frequent complication of certain tumor sites. J Pediatr Hematol Oncol 28:659–664.

   OpenUrlCrossRefPubMed
8. ↵
   1. Maas MH,
   2. Cransberg K,
   3. van Grotel M,
   4. Pieters R,
   5. van den Heuvel-Eibrink MM

   (2007) Renin-induced hypertension in Wilms tumor patients. Pediatr Blood Cancer 48:500–503.

   OpenUrlCrossRefPubMed
9. ↵
   1. Szychot E,
   2. Apps J,
   3. Pritchard-Jones K

   (2014) Wilms’ tumor: biology, diagnosis and treatment. Transl Pediatr 3:12–24.

   OpenUrl
10. ↵
    1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents

    (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Al Salloum AA,
    2. El Mouzan MI,
    3. Al Herbish AS,
    4. Al Omar AA,
    5. Qurashi MM

    (2009) Blood pressure standards for Saudi children and adolescents. Ann Saudi Med 29:173–178.

    OpenUrlPubMedWeb of Science
12. ↵
    1. Steinbrecher HA,
    2. Malone PS

    (1995) Wilms tumour and hypertension: incidence and outcome. Br J Urol 76:241–243.

    OpenUrlPubMed
13. ↵
    1. Spahr J,
    2. Demers LM,
    3. Shochat SJ

    (1981) Renin producing Wilms’ tumor. J Pediatr Surg 16:32–34.

    OpenUrlCrossRefPubMed
14. ↵
    1. Leckie BJ,
    2. Birnie G,
    3. Carachi R

    (1994) Renin in Wilms’ tumor: prorenin as an indicator. J Clin Endocrinol Metab 79:1742–1746.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Ager EI,
    2. Neo J,
    3. Christophi C

    (2008) The renin-angiotensin system and malignancy. Carcinogenesis 29:1675–1684.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Khakoo AY,
    2. Sidman RL,
    3. Pasqualini R,
    4. Arap W

    (2008) Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 68:9112–9115.

    OpenUrlAbstract/FREE Full Text
17. ↵
    1. Kim ST,
    2. Park KH,
    3. Oh SC,
    4. Seo JH,
    5. Kim JS,
    6. Shin SW,
    7. et al.

    (2012) How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology 83:354–360.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Noguchi R,
    2. Yoshiji H,
    3. Ikenaka Y,
    4. Namisaki T,
    5. Kitade M,
    6. Kaji K,
    7. et al.

    (2009) Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via antiangiogenic activities. Oncol Rep 22:355–360.

    OpenUrlPubMedWeb of Science
19. 1. Amaya K,
    2. Ohta T,
    3. Kitagawa H,
    4. Kayahara M,
    5. Takamura H,
    6. Fujimura T,
    7. et al.

    (2004) Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 25:849–856.

    OpenUrlPubMedWeb of Science
20. ↵
    1. Gong Q,
    2. Davis M,
    3. Chipitsyna G,
    4. Yeo CJ,
    5. Arafat HA

    (2010) Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 39:595–603.

    OpenUrlPubMed
21. ↵
    1. Yuge K,
    2. Miyajima A,
    3. Tanaka N,
    4. Shirotake S,
    5. Kosaka T,
    6. Kikuchi E,
    7. et al.

    (2012) Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol 19:3987–3993.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    1. Nakai Y,
    2. Isayama H,
    3. Ijichi H,
    4. Sasaki T,
    5. Sasahira N,
    6. Hirano K,
    7. et al.

    (2010) Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103:1644–1648.

    OpenUrlCrossRefPubMedWeb of Science